Resources for News Media

• Experts Discuss Grail Blood Test For Cancer, Concerns Over Quality, Overtesting

  August 11, 2023 | KFF Health News
  An article published by KFF Health News and reprinted in multiple outlets, including the Philadelphia Inquirer, looked at “multi-cancer early-detection (MCED) tests, which analyze DNA fragments in the blood for abnormalities associated with cancer.” Among the experts interviewed was the National Cancer Institute Cancer Prevention Director Philip Castle.

• NCI’s Shobha Srinivasan Discusses Agency’s Goal Of Improving Cancer Results For People In Poverty

  August 7, 2023 | Federal News Network
  Federal Drive with Tom Temin interviewed NCI Senior Advisor for Health Disparities Shobha Srinivasan about the details of the organization’s new grants. “Poverty often means less access to good health care, and therefore worse outcomes than those of the wealthy.” Now, the NCI “has awarded $50 million in grants to establish five new organizations devoted to cancer prevention and care.”
  

• Dog cancer research advances pursuit of drugs for humans and canines

  June 20, 2023 | The Washington Post
  Compelling genetic data, increased funding and growing collaborations in the past decade are pushing forward development of cancer drugs for both canines and humans

• Involving All of Society to End Cancer as We Know It

  June 10, 2023 | The ASCO Post
  This has been a year of firsts and seconds for Monica M. Bertagnolli, MD, FACS, FASCO. This past October, Dr. Bertagnolli became the 16th Director of the National Cancer Institute (NCI), the first woman and the first clinical trials cooperative group chair to hold that position. Then, 2 months later, on December 14, 2002, Dr. Bertgnolli became the first publicly known Director of the NCI to be diagnosed with cancer and to undergo treatment while heading the agency.

• NCI Program Explores Best Practices for Enrolling Underserved Groups to Precision Oncology Trials

  June 6, 2023 | Precision Medicine Online
  CHICAGO – A National Cancer Institute-funded study exploring strategies for diversifying clinical trials found community engagement, study navigators, and telemedicine showed promise in enrolling patients traditionally left out of research, but efforts to screen for and enlist study participants harboring specific biomarkers of interest weren't as successful.

• Action Needed to Hit 'Moonshot' Goal of Halving Cancer Deaths by Mid-Century

  April 17, 2023 | HealthDay
  The United States will fall short of its Cancer Moonshot goal of cutting cancer deaths by at least half over the next 25 years unless more action is taken, a new U.S. National Cancer Institute analysis concludes.

• Lung Cancer Trial Has Broader Eligibility Criteria, Overcomes Barriers

  April 14, 2023 | CURE
  The National Cancer Institute (NCI) launched the phase 3 Pragmatica-Lung Study (S2302) clinical trial evaluating Cyramza (ramucirumab) plus Keytruda (pembrolizumab) for patients with stage 3 or recurrent non-small cell lung cancer, according to a press release from the agency.

• How the cloud is letting the National Cancer Institute take the IT burden off its mission areas

  March 31, 2023 | Federal News Network
  The National Cancer Institute is keeping its IT modernization strategy pretty simple. There is cloud one and there is cloud two. All new development will reside in one of those two instances.

• The Cancer Moonshot Enters a New Phase

  January 25, 2023 | IEEE Pulse
  Moonshot-supported research has made progress in lowering cancer mortality rates, and this new initiative prioritizes diversity in research with a goal of ending cancer as we know it

Trending Topics

• Cancer Moonshot Scholars

  The Cancer Moonshot Scholars program is designed to advance cancer science while also diversifying the pool of researchers and the approaches to cancer research that NCI funds. The program seeks to enhance the number of applications submitted by Early Stage Investigators from diverse backgrounds, including those from groups identified as underrepresented) in the biomedical, clinical, behavioral, and social sciences research workforce.

• National Cancer Plan - Join Us

  People across the country and worldwide are counting on us to end cancer as we know it. Research alone will not accomplish this. To succeed, we must work together to develop strategies, share knowledge, and accelerate progress. The National Cancer Plan provides a comprehensive framework for this meaningful collaboration and unites us in acting on the vision President Biden and First Lady Biden set out in the Cancer Moonshot℠ to end cancer as we know it.

• Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry

  Article on ScienceDirect - Background: Genetic factors play an important role in prostate cancer (PCa) susceptibility; Objective: To discover common genetic variants contributing to the risk of PCa in men of African ancestry.

• White House Fact Sheet: On One Year Anniversary of Reignited Cancer Moonshot, Biden-⁠Harris Administration Announces New Actions to End Cancer as We Know It

  One year ago, President Joe Biden and First Lady Jill Biden reignited the Cancer Moonshot, setting an ambitious, achievable goal: to reduce the death rate from cancer by at least 50 percent over the next 25 years, and improve the experience of people and families living with and surviving cancer, ultimately ending cancer as we know it today.

• HER2’s Genetic Link to Breast Cancer Spurs Development of New Treatments

  HER2 is a gene that has been linked to breast cancer growth. Learn about the development of trastuzumab, a monoclonal antibody that blocks the HER2 protein, and other treatments that have improved survival for women with HER2-positive breast cancer.

• Breast Cancer—Patient Version

  Breast cancer is the second most common cancer in women after skin cancer. Mammograms can detect breast cancer early, possibly before it has spread. Start here to find information on breast cancer treatment, causes and prevention, screening, research, and statistics.

• Uterine Cancer—Patient Version

  Uterine cancers can be of two types: endometrial cancer (common) and uterine sarcoma (rare). Endometrial cancer can often be cured. Uterine sarcoma is often more aggressive and harder to treat. Start here to find information on uterine cancer treatment, causes and prevention, screening, research, and statistics.

• Cancer Treatment Vaccines

  Cancer treatment vaccines treat cancer by strengthening the body’s natural defenses against the cancer. This page covers how cancer treatment vaccines work against cancer, cancers that are treated with them, and the side effects they may cause.

• Cancer death rates among Black people declined over time, but remain higher than other racial and ethnic groups

  From 1999—2019, US rates of cancer death fell among Black people. Yet, in 2019, their rates remained higher than those of other racial and ethnic groups.

• NCI COVID-19 in Cancer Patients Study (NCCAPS)

  The NCI COVID-19 in Cancer Patients Study, or NCCAPS, is a natural history study of COVID-19 in people with cancer. The knowledge gained from this study will help doctors better manage treatment for people with cancer and COVID-19 in the future.